Study of SRF617 in Patients With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Advanced Solid Tumor

In brief

A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.

Key facts

Study ID

NCT04336098

Run by

Coherus Oncology, Inc.

People needed

85

Starts

2020-03-16

Expected to finish

2023-08-25

Last updated by the study team

2024-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope — Duarte, California, United States
• The Angeles Clinic and Research Institute — Los Angeles, California, United States
• University of Colorado — Aurora, Colorado, United States
• Moffitt Cancer Center — Tampa, Florida, United States
• Mary Crowley Cancer Research — Dallas, Texas, United States
• South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States
• University of Virginia — Charlottesville, Virginia, United States
• University of Washington — Seattle, Washington, United States
• University Health Network-Princess Margaret Cancer Centre — Toronto, Ontario, Canada
• Universite de Montreal - Centre Hospitalier de l'Universite de Montreal (CHUM) - Hopital Notre-Dame — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.